Castle Biosciences (CSTL) Earnings Date, Estimates & Call Transcripts $20.09 +0.27 (+1.36%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$19.64 -0.45 (-2.24%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Castle Biosciences Earnings Summary Castle Biosciences posted Q2 2025 earnings on August 4, 2025, reporting an EPS of $0.15, which beat the consensus estimate of -$0.51 by $0.66. Quarterly revenue was reported to be $86.18 million, above the consensus estimate of $71.53 million. With a trailing EPS of -$0.35, Castle Biosciences' earnings are expected to decrease next year, from $0.44 to ($1.51) per share. Upcoming Q3 Earnings DateNov. 3After Market ClosesEstimatedConsensus EPS (Aug. 4) -$0.51 Actual EPS (Aug. 4) $0.15 Beat By $0.66 Actual Revenue (Aug. 4) $86.18MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q) Slide DeckCSTL Upcoming EarningsCastle Biosciences' next earnings date is estimated for Monday, November 3, 2025, based on past reporting schedules. Slide DeckFull Screen Slide DeckPowered by Get Castle Biosciences Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Castle Biosciences and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCSTL Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CSTL Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Castle Biosciences Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251-$0.07-$0.07-$0.07Q2 20251-$0.51-$0.51-$0.51Q3 20251-$0.35-$0.35-$0.35Q4 20251-$0.25-$0.25-$0.25 FY 2025 4 -$1.18 -$1.18 -$1.18 Q1 20261-$0.66-$0.66-$0.66Q2 20261-$0.62-$0.62-$0.62Q3 20261-$0.47-$0.47-$0.47Q4 20261-$0.36-$0.36-$0.36 Castle Biosciences Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/3/2025(Estimated)--------8/4/2025Q2 2025-$0.51$0.15+$0.66$0.15$71.53M$86.18M5/5/2025Q1 2025-$0.08-$0.20 -$0.12-$0.90$80.40M$87.99M11/4/2024Q3 2024-$0.06$0.08+$0.14$0.08$78.55M$85.78M8/5/2024Q2 2024-$0.16$0.31+$0.47$0.31$69.95M$87.00M5/2/2024Q1 2024-$0.37-$0.09+$0.28-$0.09$68.34M$72.97M2/28/2024Q4 2023-$0.84-$0.10+$0.74-$0.10$51.32M$66.12M11/2/2023Q3 2023-$0.92-$0.26+$0.66-$0.26$44.94M$61.49M Castle Biosciences Earnings - Frequently Asked Questions When is Castle Biosciences' earnings date? Castle Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 3rd, 2025 based off last year's report dates. Learn more on CSTL's earnings history. What guidance has Castle Biosciences issued on next quarter's earnings? Castle Biosciences updated its FY 2025 earnings guidance on Monday, August, 4th. The company issued revenue guidance of $310.0 million-$320.0 million, compared to the consensus revenue estimate of $294.1 million. Did Castle Biosciences beat their earnings estimates last quarter? In the previous quarter, Castle Biosciences (NASDAQ:CSTL) reported $0.15 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.51) by $0.66. Learn more on analysts' earnings estimate vs. CSTL's actual earnings. How can I listen to Castle Biosciences' earnings conference call? The conference call for Castle Biosciences' latest earnings report can be listened to online. Listen to Conference Call How can I read Castle Biosciences' conference call transcript? The conference call transcript for Castle Biosciences' latest earnings report can be read online. Read Transcript How much revenue does Castle Biosciences generate each year? Castle Biosciences (NASDAQ:CSTL) has a recorded annual revenue of $332.07 million. How much profit does Castle Biosciences generate each year? Castle Biosciences (NASDAQ:CSTL) has a recorded net income of $18.25 million. CSTL has generated -$0.35 earnings per share over the last four quarters. What is Castle Biosciences' EPS forecast for next year? Castle Biosciences' earnings are expected to decrease from $0.44 per share to ($1.51) per share in the next year. More Earnings Resources from MarketBeat Related Companies VCYT Earnings ADUS Earnings PGNY Earnings CELC Earnings ARDT Earnings LFST Earnings NHC Earnings VRDN Earnings AVAH Earnings AHCO Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Green Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals?Why SoundHound AI's Earnings Show the Stock Can Move Higher This page (NASDAQ:CSTL) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access